aTyr Pharma, Inc. reported a consolidated net loss of $19.53 million for the second quarter of 2025, resulting in a loss of 22 cents per share. For the six months ended June 30, 2025, the net loss was $34.41 million.
Research and development expenses increased by $1.40 million to $15.38 million in Q2 2025 compared to Q2 2024, primarily due to a $1.00 million increase in manufacturing costs for potential BLA filing preparation. General and administrative expenses also increased by $1.59 million to $4.93 million, driven by higher personnel and pre-commercialization costs.
As of June 30, 2025, the company held $83.20 million in cash, cash equivalents, restricted cash, and available-for-sale investments. With the recent completion of the last patient visit in the Phase 3 EFZO-FIT™ study, topline data is on track to be reported in mid-September 2025, marking a major inflection point for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.